Trending...
- The Truth Makers: The Quantum Lie Turns a Presidential Bribery Video Into a Crisis of Reality
- One Night. One Encounter. A New Season Of Purpose
- Nextlink Internet Deploys netElastic to Modernize Its Hybrid Broadband Network
~ Philadelphia, June 13, 2024 - Clario, a leading provider of technologies and endpoint data solutions for clinical trials, has announced the U.S. Food and Drug Administration (FDA) clearance of its SpiroSphere® with the wireless COR-12 Electrocardiogram (ECG) device. This groundbreaking integration allows for the consecutive collection of spirometry and ECG data during a single site visit through Clario's SpiroSphere® platform.
The FDA 510(k) clearance marks a significant milestone in clinical trial technology, as it streamlines the process by consolidating all data into a single, unified database. This eliminates the need for separate ECG devices or multiple databases for a study, making it more efficient and cost-effective.
Originally launched in 2018, the SpiroSphere®, a smart and lightweight pulmonary function testing (PFT) device, did not include ECG functionality. However, with the introduction of the SpiroSphere® ECG featuring the wireless COR-12 ECG device, customers can now conduct integrated respiratory and cardiac safety trials on one device and one database.
More on The PennZone
Tom Stuckey, Senior Vice President of Respiratory & Precision Motion at Clario, stated that "the launch of our FDA-cleared SpiroSphere® wireless ECG device represents a significant step in improving clinical trial technology." He also emphasized their commitment to optimizing data collection, efficiency, and consistency in delivering respiratory trials with cardiac safety.
The wireless feature of the SpiroSphere® ECG not only improves patient experience by removing the need for lead wires but also maintains high-quality data collection standards. This advancement enables site clinicians to comfortably record both ECG and spirometry data in one session on a single device. It reduces burden on patients and accelerates trial timelines.
Ellen Street, Executive Vice President of Cardiac, Respiratory & Precision Motion at Clario added that "our SpiroSphere® wireless ECG focuses on the site and patient experience while maintaining high-quality data collection standards." She also highlighted the cost-effective solution this product offers for enhanced efficiency and patient experience.
For more information about the SpiroSphere® ECG and other Clario endpoint solutions, please visit Clario.com. This technological advancement is set to revolutionize respiratory trials with cardiac safety, making it easier and more efficient for sponsors to conduct comprehensive trials.
The FDA 510(k) clearance marks a significant milestone in clinical trial technology, as it streamlines the process by consolidating all data into a single, unified database. This eliminates the need for separate ECG devices or multiple databases for a study, making it more efficient and cost-effective.
Originally launched in 2018, the SpiroSphere®, a smart and lightweight pulmonary function testing (PFT) device, did not include ECG functionality. However, with the introduction of the SpiroSphere® ECG featuring the wireless COR-12 ECG device, customers can now conduct integrated respiratory and cardiac safety trials on one device and one database.
More on The PennZone
- Communities In Schools of Eastern Pennsylvania Honors United Way and Local Leaders
- New Finnish Affiliate Site Ilmaiskierrokset.com Puts Wager-Free Spins in the Spotlight
- Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
- Veterans Day Breakfast Celebration in Valley Forge to Honor America's Military Heroes
- Best Black Friday 2026 Deals on Lightweight Foldable Electric Wheelchairs – Save Up to 60%
Tom Stuckey, Senior Vice President of Respiratory & Precision Motion at Clario, stated that "the launch of our FDA-cleared SpiroSphere® wireless ECG device represents a significant step in improving clinical trial technology." He also emphasized their commitment to optimizing data collection, efficiency, and consistency in delivering respiratory trials with cardiac safety.
The wireless feature of the SpiroSphere® ECG not only improves patient experience by removing the need for lead wires but also maintains high-quality data collection standards. This advancement enables site clinicians to comfortably record both ECG and spirometry data in one session on a single device. It reduces burden on patients and accelerates trial timelines.
Ellen Street, Executive Vice President of Cardiac, Respiratory & Precision Motion at Clario added that "our SpiroSphere® wireless ECG focuses on the site and patient experience while maintaining high-quality data collection standards." She also highlighted the cost-effective solution this product offers for enhanced efficiency and patient experience.
For more information about the SpiroSphere® ECG and other Clario endpoint solutions, please visit Clario.com. This technological advancement is set to revolutionize respiratory trials with cardiac safety, making it easier and more efficient for sponsors to conduct comprehensive trials.
0 Comments
Latest on The PennZone
- New Atlas Maps the 38 States Behind Every Conversation
- Atlanta Company Launches Free, Ad-Free, Nonpartisan Voter Planning App for All 50 States Ahead of the Nov. 3 Election
- Pastor Carlton L. Aiken Sr. Celebrates 55 Years with "Sermonic Selections"
- J. Wes Seeks Jazz Musicians, Vocalists and Bands for Philadelphia Live Music Event
- NECP Promotes Chertova to Senior Business Analyst
- Security Industry Veteran Anthony Rumore Launches AegisLead to Help Security Companies Find Business and Manage Growth
- Charlie Shaw and Patrick Carragher win SEO Agency of the Year 2026
- Canadian Woman Plants 1,667 Love Stories in a Field of Peonies That Could Bloom for 100 Years
- New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX)
- Beyond the Odds: BetQL Combines Sharp Money Trends and Real Time Odds to Help Bettors Find Value
- Mark Schork and Terri Smith Honored by Philadelphia Bar Association as 'Bar Stars'
- WebDrafter Welcomes Dreamwork Exteriors as a New Marketing Client
- Glenn Lyvers Wins 2nd Place in Arizona State Poetry Society 2026 Annual Contest
- Access Control Security Shares 5 Ways Retailers Can Prevent Holiday Theft
- Bountiful Bowl Aims to Raise $50,000 to Support Meals on Wheels of the Greater Lehigh Valley
- Extreme Lead Program Highlights $27 Real Human Traffic Test for Affiliate and Network Marketers
- Longevity Academy Features Gail Humble, MD of KLOTHO SKIN in the Longevity Leaders Project
- Datavalet Named One of Quebec's Best Workplaces™ for 2026
- Phinge Corporation Engages Sheridan Ross PC for Certain Intellectual Property Matters
- Alan Hamilton of Shiver Hamilton Campbell Inducted as a Fellow of the American College of Trial Lawyers